Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Changing role of somatostatin receptor targeted drugs in NET: Nuclear Medicine's view.

× No keyword cloud information.

11 in total

1. Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice.

Authors: Mohammad Abolhassani; Adeline Guais; Edward Sanders; Frédéric Campion; Iduna Fichtner; Jacques Bonte; Gianfranco Baronzio; Giammaria Fiorentini; Maurice Israël; Laurent Schwartz
Journal: Invest New Drugs Date: 2011-06-09 Impact factor: 3.850

2. Correlation of monoclonal and polyclonal somatostatin receptor 5 antibodies in pancreatic neuroendocrine tumors.

Authors: Daniel Kaemmerer; Amelie Lupp; Luisa Peter; Elke Fischer; Stefan Schulz; Günter Klöppel; Merten Hommann
Journal: Int J Clin Exp Pathol Date: 2012-11-20

3. Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors.

Authors: Daniel Kaemmerer; Luisa Peter; Amelie Lupp; Stefan Schulz; Jörg Sänger; Richard Paul Baum; Vikas Prasad; Merten Hommann
Journal: Int J Clin Exp Pathol Date: 2012-03-25

4. Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT.

Authors: Kevin Zwirtz; Juliane Hardt; Güliz Acker; Alexander D J Baur; Marianne Pavel; Kai Huang; Winfried Brenner; Vikas Prasad
Journal: Pharmaceutics Date: 2022-06-16 Impact factor: 6.525

5. [Poorly differentiated neuroendocrine carcinoma of the larynx. Diagnostic features, treatment strategy, and prognosis].

Authors: M D Jumah; F Fleiner; S Wendt; M Pavel; M Schwabe; O Göktas
Journal: HNO Date: 2009-02 Impact factor: 1.284

6. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.

Authors: Daniel Putzer; Alexander Kroiss; Dietmar Waitz; Michael Gabriel; Tatjana Traub-Weidinger; Christian Uprimny; Elisabeth von Guggenberg; Clemens Decristoforo; Boris Warwitz; Gerlig Widmann; Irene Johanna Virgolini
Journal: Eur J Nucl Med Mol Imaging Date: 2012-11-14 Impact factor: 9.236

Review 7. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues.

Authors: Edgar J Rolleman; Marleen Melis; Roelf Valkema; Otto C Boerman; Eric P Krenning; Marion de Jong
Journal: Eur J Nucl Med Mol Imaging Date: 2009-11-14 Impact factor: 9.236

8. THE ROLE OF TUMOR-SEEKING RADIOPHARMACEUTICALS IN THE DIAGNOSIS AND MANAGEMENT OF ADRENAL TUMORS.

Authors: V Vukomanovic; M Matovic; A Djukic; V Ignjatovic; K Vuleta; S Djukic; I Simic Vukomanovic
Journal: Acta Endocrinol (Buchar) Date: 2020 Jul-Sep Impact factor: 0.877

9. Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours.

Authors: Marleen Melis; Magda Bijster; Monique de Visser; Mark W Konijnenberg; Jan de Swart; Edgar J Rolleman; Otto C Boerman; Eric P Krenning; Marion de Jong
Journal: Eur J Nucl Med Mol Imaging Date: 2009-12 Impact factor: 9.236

10. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study.

Authors: Edward M Wolin; Ke Hu; Gareth Hughes; Emmanuel Bouillaud; Vanessa Giannone; Karina Hermosillo Resendiz
Journal: Cancer Chemother Pharmacol Date: 2013-06-14 Impact factor: 3.333